Overview |
bs-0578R |
Pro-Collagen 1 Polyclonal Antibody |
WB, ELISA, FCM, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
This antibody is produced using a peptide that is found in the C-terminal propeptide region. |
Human, Mouse, Rat, Dog, Rabbit, Fish |
Cow, Sheep, Horse |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human Collagen I C-terminal propeptide |
1321-1400/1464 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
1277 |
Secreted, Extracellular matrix |
Collagen alpha-1(I) chain; Alpha-1 type I collagen; COL1A1, Pro-collagen 1. |
This gene encodes the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos syndrome Classical type, Caffey Disease and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the growth factor. Two transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene.
Type I collagen levels have been linked to bone growth and formation. Levels of the C-terminal propeptide are indicative of collagen production in vivo. Elevated levels of C-terminal propeptide have been shown in diseases associated with high levels of bone turnover, including Pagets disease, hyperthyroidism, primary hyperparathyroidism and renal osteodystrophy. Slightly elevated levels of C-terminal propeptide have also been documented in some women in early menopause. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
FCM |
1:20-100 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |